Palantir Faces Scrutiny as UK MPs Demand Closer Look at Data Use Amid NHS Adoption
A new push for transparency has emerged in the UK, as lawmakers demand greater scrutiny of data use by multinational technology company Palantir. The move comes in response to a recent NHS guidance requiring all hospitals to incorporate Palantir’s software by April, sparking a heated debate.
The guidance, which was issued earlier this year, aimed to streamline data sharing and improve healthcare services across England. However, its adoption has raised concerns about patient privacy and data security. Critics argue that Palantir’s software poses potential risks to both, citing the company’s close ties to law enforcement and intelligence agencies worldwide.
Palantir has since defended its record on data use, citing the numerous safeguards and protocols in place to protect sensitive patient information. A spokesperson emphasized the company’s ‘no-litmus’ approach to data, stating that Palantir does not sell or use the data for its own purposes, while maintaining that it is used solely for the betterment of healthcare services.
The tech giant has long been a subject of controversy, particularly regarding its involvement in surveillance programs and its close ties to US government agencies. As the UK continues to grapple with these issues, lawmakers are pushing for greater transparency and accountability.
Several key lawmakers have written to the UK’s health secretary, voicing their concerns over Palantir’s software adoption. They have called for a thorough risk assessment, citing potential risks to patient data and the NHS’ reputation.
Palantir’s software is set to be used by every NHS hospital in England by April this year. As of now there’s no public data available on whether NHS hospitals have already begun the integration and to what extent their usage of the software has contributed towards better healthcare delivery.
This is a developing story. Stay tuned for more updates.
This article may be prepared with the assistance of artificial intelligence (AI) and is reviewed before publication. While we aim for accuracy and timeliness, readers should verify important facts from official or primary sources. If you believe any information is inaccurate or that any content infringes your rights, please contact ainewsbreaking.com for review and appropriate action.
